Get the Daily Brief
Latest Biotech News
GLP-1 precision medicine
Multiple genetics studies are moving GLP-1 obesity therapy toward more individualized targeting by linking patient variants to weight-loss magnitude and side-effect risk. 23andMe Research...
Neuroblastoma vulnerability via NO–mTOR axis
A new mechanistic study identifies a neuroblastoma survival pathway that may be druggable by disrupting neuronal nitric oxide synthase (nNOS) signaling. Researchers from The Hebrew University of...
Salk expands mitochondrial DNA modeling platform
Salk Institute researchers unveiled a scalable stem-cell platform to generate mitochondrial DNA mutant mice, addressing a key bottleneck in modeling the full diversity of inherited mitochondrial...
Precision contact lens for glaucoma management
A new smart contact lens approach pairs continuous intraocular pressure (IOP) monitoring with closed-loop, adaptive drug delivery for glaucoma. In Science Translational Medicine, Terasaki...
Immunotherapy to boost pancreatic response
A study from MD Anderson identifies DPY30 as a key epigenetic regulator linked to genomic stability under DNA replication stress in pancreatic tumors. Researchers at The University of Texas MD...
Pediatric VTE prevention guidelines
ASH and ISTH released new clinical guidance for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism (VTE) outside cardiac indications. Published in Blood Advances,...
New clinical trial concept: gut microbiome intervention in kidney cancer
University Hospitals Seidman Cancer Center launched S2419 BioFront, a Phase III program that integrates a gut microbiome intervention into an advanced kidney cancer treatment protocol. The study...
Sidewinder raises Series B for bispecific ADCs
Sidewinder Therapeutics secured $137 million in an oversubscribed Series B round to advance bispecific antibody-drug conjugates toward clinical testing. Backed by OrbiMed and multiple investors,...
Gilead expands ADC platform with Tubulis deal
Gilead agreed to acquire German ADC specialist Tubulis to expand its antibody-drug conjugate capabilities, with deal terms reaching up to $5 billion. The acquisition includes $3.15 billion...
Neurocrine acquires Soleno for PWS hyperphagia franchise
Neurocrine Biosciences announced a $2.9 billion acquisition of Soleno Therapeutics, adding the FDA-approved Vykat XR (diazoxide choline) therapy for Prader-Willi syndrome hyperphagia. Under the...
Corporate M&A reshapes Gilead’s oncology engine with next-gen ADC platform
Gilead Sciences agreed to acquire German ADC specialist Tubulis for $3.15 billion upfront, with up to $1.85 billion in milestones, expanding the company’s antibody-drug conjugate pipeline beyond...
Neurocrine locks in Prader-Willi hyperphagia franchise via Soleno acquisition
Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, aiming to broaden its marketed endocrinology and rare-disease portfolio. The acquisition includes Vykat XR (diazoxide...
Regulatory and policy push: FDA proposes faster early trials and “domestic-first” incentives
The FDA is using its proposed 2027 budget to lay out policy ideas intended to speed early clinical development in the U.S. and encourage domestic drug manufacturing. FDA Commissioner Marty Makary...
Diagnostics access expands: at-home HPV self-collection gets FDA 510(k) clearance
Waters received FDA 510(k) clearance for its BD Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, enabling an at-home workflow for high-risk HPV screening. The test is designed to...
AI-enabled immunology readouts: new single-cell method tracks RNA and protein together
Researchers reported CIPHER-seq, a single-cell platform designed to measure RNA and proteins simultaneously in the same immune cell, aimed at closing the gap between cytokine gene expression and...
Breast cancer imaging: new AI model targets DCE-MRI tumor segmentation
A new AI approach for breast cancer imaging, RST2G, was reported to improve dynamic contrast-enhanced MRI (DCE-MRI) segmentation performance by combining residual-guided spatiotemporal transformer...
Oncology testing expansion: Grail integrates Galleri ordering into Epic EHR
Grail partnered with Epic to integrate its Galleri multi-cancer early detection test into Epic’s electronic health record platforms, allowing clinicians to order the test within standard EHR...
Rare disease therapeutics: For patients with Vykat XR’s success backdrop, gene-to-drug translation continues with targeted platforms
Insilico Medicine announced ISM6200, a selective NR3C1 (glucocorticoid receptor) inhibitor it positions as best-in-class for multiple indications including ovarian cancer, Cushing’s syndrome,...
Clinical trial readout: Daratumumab shows signal in early myeloma stages
The Phase II D-PRISM study reported promising efficacy for daratumumab in early multiple myeloma stages, including high-risk MGUS and low-risk smoldering multiple myeloma. The study is framed as...
Biotech funding: Jeito Capital closes $1.2B fund for independent clinical-stage European biopharma
Jeito Capital, a prominent European biotech investor, raised $1.2 billion for its next fund (Jeito II), positioning it as the largest ever for a fully independent European fund focused on...